SOURCE: China Aoxing Pharmaceutical Co., Inc.

March 01, 2010 08:00 ET

China Aoxing Pharmaceutical Company Announce March Investor Conferences Participation

NEW YORK, NY--(Marketwire - March 1, 2010) - China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced the Company's participation in the following conferences.

--  Rodman & Renshaw Annual China Investment Conference, to be held
    March 7-9, 2010 at the Regent Hotel, Beijing, China. Management present
    at 11:05 am Beijing Time on March 8 and meet with institutional
    investors throughout March 8 and 9;

--  Roth 22nd Annual OC Growth Stock Conference, to be held March 14-17,
    2010 at The Ritz-Carlton, Laguna Niguel, California. Management present
    at 8:00 am Pacific Time on March 17 and meet institutional investors
    throughout March 16 and 17.

For further details, please contact your institutional sales representative.

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. It has international strategic alliances with QRxPharma Limited and American Oriental Bioengineering, Inc. (NYSE: AOB) in commercializing narcotic and pain management products for China and ex-China markets. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, China Aoxing has China's largest and the most advanced manufacturing facility for highly regulated narcotic medicines, addressing a very under-served and fast-growing market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China. For more information:

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact Information